Orbital ATK, Inc. (OA) Ups & Downs At Street Tone With Intercept Pharmaceuticals, Inc. (ICPT)

0
78

Orbital ATK, Inc. (NYSE:OA) taking place in active move after fell -0.25% to the trading price of $132.64 in latest session.

Orbital ATK (NYSE:OA) declared that it has been awarded a contract worth as much as $350 million from the U.S. Navy to continue full-rate production (FRP) of the AGM-88E Advanced Anti-Radiation Guided Missile (AARGM). With an initial award of $157 million for FRP Lot 6 U.S. Navy missiles, this contract will deliver advanced capability to our warfighters. The contract also includes an option for FRP Lot 7 missiles. The contract covers all-up round missiles and captive air training missiles for the U.S. Navy, Italian Air Force and other allies through Foreign Military Sales orders. AARGM provides the U.S. Navy and our allies with critical mission capabilities to counter the accelerating proliferation of surface-to-air threats.

“It’s battlefield is rapidly evolving and the number of threats emerging around the world continues to grow. AARGM is an affordable solution that provides advanced capabilities to those protecting our nation and allies each and every day,” said Cary Ralston, Vice President and General Manager of Orbital ATK’s Defense Electronic Systems Division of the company’s Defense Systems Group. “AARGM’s game-changing technology is vital to the warfighter’s success and equips pilots with the most advanced solution to detect and defeat surface-to-air-threats.”

AARGM is a supersonic, air-released tactical missile system, upgrading legacy AGM-88 HARM systems with advanced capability to perform destruction of enemy air defenses. AARGM is the most advanced system for pilots, with in-cockpit, real-time electronic order- of-battle situational awareness against ’s modern surface-to-air threats. It is able to rapidly engage traditional and non-traditional advanced land- and sea-based air-defense threats, as well as striking time-sensitive targets.

Its 52-week range quite noticeable, lower range was $85.46% and hit highest level of $-0.56%. The overall volume in the last trading session was 1.17 Million shares. The firm shares 50 day moving average were calculated 20.61%. The firm’s institutional ownership remained 85.20% while insider ownership included 0.80%.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) trade at $57.01 by plummeted -3.11% in most recent trading session with share volume of 4.08 Million. Pomerantz LLP reported that a class action lawsuit has been filed against Intercept Pharmaceuticals, Inc. (ICPT) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and docketed under 17-cv-07371, is on behalf of a class consisting of investors who purchased or otherwise purchased Intercept securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.

Intercept Pharmaceuticals, Inc. manufactures and markets biopharmaceutical products. The Company focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry. The Company’s lead product candidate, Ocaliva (obeticholic acid, or OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid, that selectively binds to and activates the farnesoid X receptor, or FXR. On May 31, 2016, Intercept reported that the U.S. Food and Drug Administration (“FDA”) had authorized Ocaliva for the treatment of patients with primary biliary cholangitis (“PBC”).

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Ocaliva entailed undisclosed safety risks, including death, to patients suffering from PBC; and (ii) as a result of the foregoing, Intercept’s public statements were materially false and misleading at all relevant times.

The share is moved forward to its percent change from 52-week low of -2.71% and hanging back from its percent change from 52-week high of -67.00%. Shares price moved down from its 50 days moving average with -46.86% and remote positively from 200 days moving average with -49.90%.

LEAVE A REPLY

Please enter your comment!
Please enter your name here